Abstract
An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.
| Original language | English |
|---|---|
| Pages (from-to) | 879-891 |
| Number of pages | 13 |
| Journal | Infectious Disease Clinics of North America |
| Volume | 26 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2012 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Microbiology (medical)
- Infectious Diseases
Cite this
The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus. / Jenkins, Erin T.; Jensen, Donald M.
In: Infectious Disease Clinics of North America, Vol. 26, No. 4, 12.2012, p. 879-891.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
AU - Jenkins, Erin T.
AU - Jensen, Donald M.
PY - 2012/12
Y1 - 2012/12
N2 - An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.
AB - An increased understanding of viral kinetics has allowed clinicians to tailor therapy for hepatitis C virus through identifying patients who have the best chance of viral eradication and those for whom therapy will likely fail. Nonetheless, sustained viral response rates with pegylated interferon (PegIFN) and ribavirin remain disappointingly low. However, exciting advancements in the field of hepatitis C therapy include the development of new direct-acting antiviral agents, which offer much higher rates of sustained viral eradication when used in combination with PegIFN and ribavirin.
UR - http://www.scopus.com/inward/record.url?scp=84876450432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876450432&partnerID=8YFLogxK
U2 - 10.1016/j.idc.2012.08.007
DO - 10.1016/j.idc.2012.08.007
M3 - Review article
C2 - 23083821
AN - SCOPUS:84867685800
VL - 26
SP - 879
EP - 891
JO - Infectious Disease Clinics of North America
JF - Infectious Disease Clinics of North America
SN - 0891-5520
IS - 4
ER -